WNK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14845612	1.00	2/20
SCHEMBL18808417	1.00	2/20
SCHEMBL20333841	1.00	2/20
SCHEMBL24606232	1.00	2/20
SCHEMBL25597915	0.78	2/20
SCHEMBL23259513	0.71	2/20
SCHEMBL19407825	0.70	2/20
SCHEMBL14231500	0.69	2/20
SCHEMBL10026708	0.68	2/20
SCHEMBL29887253	0.68	2/20
SCHEMBL22765547	0.66	2/20
SCHEMBL27350404	0.56	2/20
SCHEMBL868254	1.00	1/20
SCHEMBL13385799	1.00	1/20
SCHEMBL29384284	1.00	1/20
SCHEMBL29403654	1.00	1/20
SCHEMBL30500616	1.00	1/20
SCHEMBL31060676	1.00	1/20
SCHEMBL28589747	0.87	1/20
SCHEMBL13555007	0.87	1/20

Clinical trials — most relevant to WNK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
Salt Loading and Thiazide Intervention Study	PHASE4	COMPLETED
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study	PHASE4	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Atomoxetine in Melanocortin Obesity Syndrome	PHASE2	NOT_YET_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure	EARLY_PHASE1	COMPLETED
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Defining the Brain Phenotype of Children With Williams Syndrome	nan	RECRUITING
Transauricular Vagus Nerve Stimulation for Chronic Whiplash Associated Disorders	nan	RECRUITING
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Biomarkers in Samples From Patients With Endometrial Cancer	nan	WITHDRAWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Podocyts Integrity in Glomerular Diseases	nan	UNKNOWN
HYPGENE-Genetics Fitness Obesity & Risk of Hypertension	nan	COMPLETED
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Establishment of Aldosterone and Renin Reference Range	nan	UNKNOWN
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions	nan	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a WNK2 binder may also engage these)

Protein	Name	Similarity
Q3UH66	—	0.999	Q3UH66 →
Q80UE6	—	0.992	Q80UE6 →
Q96J92	—	0.990	Q96J92 →
Q7TPK6	—	0.988	Q7TPK6 →
Q9JL04	—	0.988	Q9JL04 →
O08919	—	0.987	O08919 →
Q6R2V0	—	0.987	Q6R2V0 →
Q9UDV7	—	0.987	Q9UDV7 →
Q5VV67	—	0.987	Q5VV67 →
O14512	—	0.986	O14512 →
TET3	Methylcytosine dioxygenase TET3	0.986	landscape →
Q8BWQ5	—	0.986	Q8BWQ5 →
P48031	—	0.986	P48031 →
Q9H4Z2	—	0.986	Q9H4Z2 →
Q6NSM8	—	0.986	Q6NSM8 →
PGR	Progesterone receptor	0.986	landscape →
Q63803	—	0.986	Q63803 →
O54963	—	0.986	O54963 →
Q6NZN1	—	0.986	Q6NZN1 →
P0C7M4	—	0.985	P0C7M4 →
Q63449	—	0.985	Q63449 →
CBX4	E3 SUMO-protein ligase CBX4	0.985	landscape →
Q3UIZ8	—	0.985	Q3UIZ8 →
Q60700	—	0.985	Q60700 →
Q91X45	—	0.985	Q91X45 →
Q4JF29	—	0.985	Q4JF29 →
A7X8C9	—	0.985	A7X8C9 →
O70405	—	0.984	O70405 →
Q9P1Z0	—	0.984	Q9P1Z0 →
Q8BSD5	—	0.984	Q8BSD5 →